The role of photodynamic therapy in overcoming cancer drug resistance

被引:266
作者
Spring, Bryan Q. [1 ,2 ]
Rizvi, Imran [1 ,2 ,3 ]
Xu, Nan [1 ,2 ,4 ,5 ]
Hasan, Tayyaba [1 ,2 ,6 ,7 ]
机构
[1] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[4] Shanghai East Hosp, Dept Dermatol, Shanghai, Peoples R China
[5] Tongji Univ, Shanghai 200092, Peoples R China
[6] Harvard Univ, Div Hlth Sci & Technol, Cambridge, MA 02138 USA
[7] MIT, Cambridge, MA 02139 USA
基金
美国国家卫生研究院;
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; PHASE-II TRIAL; OVARIAN-CANCER; C-MET; PHTHALOCYANINE TETRASULFONATE; 5-AMINOLEVULINIC ACID; 3-DIMENSIONAL MODEL; CROSS-RESISTANCE;
D O I
10.1039/c4pp00495g
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Many modalities of cancer therapy induce mechanisms of treatment resistance and escape pathways during chronic treatments, including photodynamic therapy (PDT). It is conceivable that resistance induced by one treatment might be overcome by another treatment. Emerging evidence suggests that the unique mechanisms of tumor cell and microenvironment damage produced by PDT could be utilized to overcome cancer drug resistance, to mitigate the compensatory induction of survival pathways and even to re-sensitize resistant cells to standard therapies. Approaches that capture the unique features of PDT, therefore, offer promising factors for increasing the efficacy of a broad range of therapeutic modalities. Here, we highlight key preclinical findings utilizing PDT to overcome classical drug resistance or escape pathways and thus enhance the efficacy of many pharmaceuticals, possibly explaining the clinical observations of the PDT response to otherwise treatment-resistant diseases. With the development of nanotechnology, it is possible that light activation may be used not only to damage and sensitize tumors but also to enable controlled drug release to inhibit escape pathways that may lead to resistance or cell proliferation.
引用
收藏
页码:1476 / 1491
页数:16
相关论文
共 126 条
[11]   Mechanisms of Resistance to Photodynamic Therapy [J].
Casas, A. ;
Di Venosa, G. ;
Hasan, T. ;
Batlle, Al. .
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (16) :2486-2515
[12]  
Casas A, 2006, INT J ONCOL, V29, P397
[13]   Photodynamic therapy and anti-tumour immunity [J].
Castano, Ana P. ;
Mroz, Pawel ;
Hamblin, Michael R. .
NATURE REVIEWS CANCER, 2006, 6 (07) :535-545
[14]   Verteporfin-Based Photodynamic Therapy Overcomes Gemcitabine Insensitivity in a Panel of Pancreatic Cancer Cell Lines [J].
Celli, Jonathan P. ;
Solban, Nicolas ;
Liang, Alvin ;
Pereira, Stephen P. ;
Hasan, Tayyaba .
LASERS IN SURGERY AND MEDICINE, 2011, 43 (07) :565-574
[15]   Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization [J].
Celli, Jonathan P. ;
Spring, Bryan Q. ;
Rizvi, Imran ;
Evans, Conor L. ;
Samkoe, Kimberley S. ;
Verma, Sarika ;
Pogue, Brian W. ;
Hasan, Tayyaba .
CHEMICAL REVIEWS, 2010, 110 (05) :2795-2838
[16]   In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment [J].
Chang, Sung K. ;
Rizvi, Imran ;
Solban, Nicolas ;
Hasan, Tayyaba .
CLINICAL CANCER RESEARCH, 2008, 14 (13) :4146-4153
[17]   Tumor vascular permeabilization by vascular-targeting photosensitization: Effects, mechanism, and therapeutic implications [J].
Chen, B ;
Pogue, BW ;
Luna, JM ;
Hardman, RL ;
Hoopes, PJ ;
Hasan, T .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :917-923
[18]   Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy [J].
Chen, B ;
Pogue, BW ;
Hoopes, PJ ;
Hasan, T .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (04) :1216-1226
[19]   Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas [J].
Cincotta, L ;
Szeto, D ;
Lampros, E ;
Hasan, T ;
Cincotta, AH .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1996, 63 (02) :229-237
[20]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825